Laura Sena
@laurasenamd
Followers
633
Following
886
Media
13
Statuses
145
Physician-scientist at JHU interested in prostate cancer, metabolism, and anything that might improve outcomes for patients with cancer
Baltimore, MD
Joined December 2019
Truly a team effort, spanning institutions and disciplines @melissaabel20 @Dr_JeannyAC @ArlenParlen @karen_autio @mbilusic @PChoyke @DeborahCitrin @JulieGr28180604 @FatimaKarzai @MarkowskiGUOnc @CathyHandy @RPachynski @krishnan_patel @EdwinPosadasMD @laurasenamd @xiaoweimd
.@theNCI's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. Co-authored by @davidjeinstein and @Dr_RaviMadan. Read the full article. https://t.co/2VErPOonZ1
#prostatecancer #pcsm
1
3
5
#EMBARK didn’t write the book📕on #BCR📈#ProstateCancer-it is merely the first chapter What do #BCR trials look like in the #PSMA🩻era? 30+experts met @theNCI🏛️ to provide a roadmap🧭 @JCO_ASCO @ASCO @PCF_Science @APCCC_Lugano @urotoday
https://t.co/ePbf8j7KQU
ascopubs.org
PURPOSEBiochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasens...
1
19
47
We are excited to open a clinical trial to assess how metabolic changes induced by water-only fasting affects the immune response to prostate cancer. Spread the word – I’m happy to discuss with any interested candidates.
0
1
7
Intratumoral heterogeneity drives therapy resistance in metastatic #ProstateCancer. @laurasenamd @hopkinskimmel joins @AndreaMiyahira @PCFnews discussing a detailed analysis of a patient's disease progression over seven years, Dr. Sena demonstrates how distinct cancer cell
0
4
14
Abs#45 @asco #GU25 Prelim data shows near term metastatic progression (conventional imaging) is a rare event in #PSMA+ #BCR #ProstateCancer Are we overtreating pts w/ median age of 70+ based on lack of understanding of #PSMA? This study continues… https://t.co/7hwIxW2ra9
1
15
35
Table 22 YIA speed networking poetry competition 🗳️ vote with a like #pcfretreat24 @PCF_Science @PCFnews
0
5
10
1/12 Thrilled that our story on HSD3B1 in ENZAMET is out @jclinicalinvest @the_asci! This is a new level of evidence for an inherited physiologic driver of prostate cancer mortality & potential treatment strategies! @PCF_Science @ASCO @AACR @ACS_Research
2
36
72
Nikki Williams @nciccr_gmb @NCIResearchCtr presented data from a study of Prospective #PSMA🩻 Monitoring #BCR #ProstateCancer #ASC024
https://t.co/0RQSZEhdoI Pts are willing to defer therapy after a discussion of known risks/benefits Accrual continues https://t.co/xCEFXIDiRK
1
6
15
Congratulations to @jonnatansheila and @AnoushkaKadam for graduating today! I’m so proud and so excited for your bright futures in research @JohnsHopkinsSPH
0
0
12
Congrats to Catherine Marshall from John Hopkins!
1
10
62
🚨We are hiring a Research Assistant to help us supercharge CAR T cells! Candidates of all experience levels are encouraged to apply. Some lab experience is required, mouse experience is preferred. 2-year minimum commitment. Please retweet! Apply here: https://t.co/qsOazgWEyv
0
44
89
The Thompson lab is officially live! Excited to announce that I recently accepted a faculty position @JohnsHopkinsMMI studying immunometabolic regulation of vaccine responses. Kicking off the new lab with my first purchase, obviously a @CytekBio flow cytometer!
8
6
47
We are proud to share our Co-Founder and CEO Dr. Philip Kantoff has been awarded the @ASCO Excellence in Teaching Award, underscoring ASCO’s belief that teaching is a vital part of #cancer care and the future of cancer medicine. For more, visit: https://t.co/0dHc1w3xl0
#ASCO2024
1
3
18
Cell delivery > drug delivery ? My group has engineered velocity receptors to actively transport CAR T cells inside solid tumors. Unlike traditional drug delivery, we can exploit active transport, active sensing through cytokines and chemotaxis of cells https://t.co/nRlJ2PDMai
8
42
233
Congratulations @MarkowskiGUOnc @EAntonarakis! Some exciting discoveries are that responders have higher density of TILS in PRE-TX bx and BAT induces inflammatory gene signatures in responders in association with downregulation of MYC
Out today (Jan 2): BAT plus Nivo produces PSA responses of 40%, objective responses of 24%, and is linked to higher PD-1 levels and inflammatory gene sig. Congrats to @MarkowskiGUOnc for leading this IIT, and to @bmsnews and @PCFnews for funding it. https://t.co/YHBhzIg4c9
0
3
16
Beautifully crafted piece by @DrSidMukherjee on Cancer Promotion Featuring Allan Balmain and @CharlesSwanton
https://t.co/rwnYEVc214
newyorker.com
We routinely test for chemicals that cause mutations. What about the dark matter of carcinogens—substances that don’t create cancer cells but rouse them from their slumber?
0
37
107
Happy holidays from our research group to yours. May your data be better than your white elephant gift 😂 @varshavakkala @jonnatansheila @AnoushkaKadam
2
0
20
Lots to discuss w/#EMBARK... Data does NOT apply to all BCR #ProstateCancer pts Median PSA is ~5 and PSA DT is ~5. But the breakdown of benefit suggests that the benefits were less clear in pts with a PSA DT 6+ months. Important consideration when deciding who NOT to treat
In patients with high-risk biochemically recurrent prostate cancer, treatment with enzalutamide and leuprolide improved metastasis-free survival as compared with leuprolide alone. Read the full results of the EMBARK phase 3 trial):
4
14
55